Peer-reviewed veterinary case report
Aglepristone before surgery helps dogs with progesterone-positive
By Guil-Luna, S et al.·Published in Veterinary and comparative oncology·2017·Department of Comparative Pathology, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prognostic impact of neoadjuvant aglepristone treatment in clinicopathological parameters of progesterone receptor-positive canine mammary carcinomas.
- Species:
- dog
Plain-English summary
Fifty female dogs with mammary tumors were treated with a medication called aglepristone before surgery to see if it could help improve their chances of recovery. The study found that dogs with certain types of tumors, specifically those that were smaller than 3 cm and had lower growth rates, had a longer disease-free period after treatment. While more research is needed, the results suggest that aglepristone could be a helpful option for managing these types of tumors in dogs.
People also search for: dog mammary tumor treatment · aglepristone for dog cancer · canine mammary carcinoma prognosis
Abstract
Neoadjuvant treatment of canine mammary carcinomas with the progesterone receptor (PR) antagonist aglepristone has a PR expression-related inhibiting effect on proliferation index (PI). The aim of this study was to evaluate the effect of the treatment in the disease-free period (DFP) and overall survival (OS) of canine mammary carcinomas. Fifty female dogs with mammary carcinomas were treated with aglepristone (n = 34) or oil vehicle (n = 16) before surgery (day 15). PR expression and PI were analysed by immunohistochemistry in samples taken at days 1 and 15. Epidemiological and clinicopathological data were assessed. DFP and OS data were retrieved every 4-6 months for at least 24 months after surgery. Aglepristone treatment increased DFP of animals bearing PR+ tumours with size smaller than 3 cm, complex and mixed tumours, with histologic grades I and II, and with PI ≤ 10%. Although further studies are necessary, current evidence points to treatment with aglepristone as useful for the management of canine mammary tumours.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26781329/